Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

医学 以兹提米比 冠状动脉疾病 内科学 他汀类 心脏病学 经皮冠状动脉介入治疗 胃肠病学 心肌梗塞
作者
Kārlis Trušinskis,Maris Lapsovs,Baiba Kokina,Mairita Karantajere,Evija Knoka,Laima Caunite,Sanda Jēgere,Inga Narbute,Dace Sondore,Ana Sofia Grave,Indulis Kumsārs,Andrejs Ērglis
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:44 (Supplement_2) 被引量:2
标识
DOI:10.1093/eurheartj/ehad655.1313
摘要

Abstract Background Low-density lipoprotein cholesterol (LDL-C) has a causal role in atherosclerotic cardiovascular disease. Genetic studies and variability in individual response to lipid-lowering therapies suggest combining hypolipidaemic medications with different mechanisms of action. Purpose The aim of this study was to evaluate the effect of triple inclisiran-based hypolipidaemic therapy in patients not reaching LDL-C target on maximum statin/ezetimibe treatment. Methods This prospective study enrolled 37 stable coronary artery disease patients admitted for elective percutaneous coronary intervention after 4-6 weeks on maximum tolerated statin and/or ezetimibe therapy during run-in period. Afterwards, patients with LDL-C level >1.8 mmol/l at the time of inclusion were assigned to receive add-on inclisiran (triple therapy group). In all participants near-infrared spectroscopy (NIRS) was performed at baseline and after 15 months for atherosclerotic plaque evaluation in the segment of interest, defined as 20-50% lesion in the proximal or middle third of a coronary artery. Statistical analysis was carried out with SPSS Statistics software. Results Average LDL-C level among screened patients was 2.81 (±1.17) mmol/l. In 19 patients LDL-C level remained >1.8 mmol/l on maximally tolerated statin and/or ezetimibe treatment, and after 15 months of triple therapy mean LDL-C reached 1.81 (±1.02) mmol/l with a significant LDL-C percentage change of 35.59% (95%CI -47.31 to -9.18, P=0.006) in this group. 17 patients continued statin/ezetimibe as mono or dual treatment and at 15-month follow-up mean LDL-C level comprised 1.67 (±0.61) mmol/l among these participants. According to NIRS data, maximum lipid-core burden index within 4 mm (maxLCBI4 mm) was significantly reduced by 28.85 (95%CI -189.39 to 17.64, P=0.041) in triple therapy group and by 114.72 in mono or dual therapy group (-194.76 to 23.01, P=0.004), with no statistically significant difference established between both groups (P=0.494). Conclusions Triple therapy demonstrated significant atherosclerotic plaque lipid content reduction along with LDL-C level lowering in patients with insufficient effectiveness of statin/ezetimibe treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
斯文钢笔完成签到,获得积分10
刚刚
1秒前
幽默的问梅完成签到,获得积分10
1秒前
1秒前
1秒前
酷波er的应助被阿业采纳,获得10
2秒前
2秒前
大模型的应助被wyc采纳,获得10
2秒前
无问西东给WYL的求助进行了留言
3秒前
拼搏一曲完成签到,获得积分10
3秒前
顺利毕业发布了新的文献求助10
3秒前
ggb发布了新的文献求助10
3秒前
TT完成签到,获得积分10
4秒前
姜海绵发布了新的文献求助10
4秒前
4秒前
4秒前
thisky发布了新的文献求助30
4秒前
秋风的应助被老迟到的越泽采纳,获得20
5秒前
5秒前
Ray发布了新的文献求助10
6秒前
6秒前
小荀完成签到,获得积分10
6秒前
6秒前
今后的应助被qin202569采纳,获得10
7秒前
7秒前
7秒前
8秒前
风吹麦浪的应助被Chen采纳,获得10
8秒前
renpp822发布了新的文献求助10
8秒前
无花果的应助被corleeang采纳,获得10
9秒前
情怀的应助被lee采纳,获得10
9秒前
9秒前
9秒前
1097发布了新的文献求助10
10秒前
10秒前
10秒前
张建秀发布了新的文献求助30
10秒前
11秒前
小吉完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124